A randomized comparison of four courses of standard-dose multiagent chemotherapy versus three courses of high-dose cytarabine alone in post-remission therapy for acute myeloid leukemia in adults: the JALSG AML201 study. /// Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. /// Blood. 2011; 117:2366-2372.
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 Study. /// Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. /// Blood. 2011;117:2358-2365.
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. /// Ono T, Miyawaki S, Kimura F, Kanamori H, Ohtake S, Kitamura K, Fujita H, Sugiura I, Usuki K, Emi N, Tamaki S, Aoyama Y, Kaya H, Naoe T, Tadokoro K, Yamaguchi T, Ohno R, Ohnishi K; for the Japan Adult Leukemia Study Group. /// Leuk Res. 2011;35:598-603.
Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. /// Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Atsuta Y, Sakamaki H, Kawa K, Morishima Y, Ohnishi K, Naoe T, Ohno R. /// Leukemia. 2011;25 :41-47.
Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. /// Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake J, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y, Hatsumi N, Ohtake S, Sakamaki H, Ohnishi K, Miyawaki S, Ohno R, Naoe T. /// Int J Hematol. 2011;93:66-73.
A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matced sibling donor. /// S Kako, S Morita, H Sakamaki, H Ogawa, T Fukuda, S Takahashi, H Kanamori, M Onizuka, K Iwato, R Suzuki, Y Atsuta, T kyo, T Sakura, I Jinnai, J akeuchi, Y Miyazaki, S Miyawaki, K Ohnishi, T Naoe and Y Kanda. /// Leukemia 2011;25:259-265.
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia(AML):Japan Adult Leukemia Study Group(JALSG)-AML206 study. /// N Usui, A Takeshita, C Nakaseko, N Dobashi, H Fujita, H Kiyoi, Y Kobayashi, T Sakura, Y Yahagi, K Shigeno, C Ohwada, Y Miyazaki, S Ohtake, S Miyawaki, T Naoe and K Ohnishi for the Japan Adult Leukemia Study Group. /// Cancer Science 2011;102:1358-1365.
Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia:10-year results of the Japan Adult Leukemia Study Group APL97 study. /// T Ono, A Takeshita, M Iwanaga, N Asou, T Naoe, and R Ohno for he Japan Adult Leukemia Study Group. /// Haematologica 96(1);174-175, 2011
2011年～2020年の論文
【論文タイトル /// 全著者名 /// 掲載誌】
Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. /// K Ohnishi, C Nakaseko, J takeuchi, S Fujisawa, T Nagai, H Yamazaki, T Tauchi, K Imai, N Mori, F Yagasaki, Y Maeda, N Usui, Y Miyazaki, K Miyamura, H Kiyoi, H Ohtake, T Naoe and for the Japan Adult Leukemia Study Group. /// Cancer Sci 103;1071-1078. 2012
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for eldery patients with acute myeloid leukemia:the JALSG GML200 Study. /// A wakita, H Ohteke, S Takada, F Yagasaki, H Komatsu, Y Miyazaki, et al. /// Int J Hematol 96(4):485-491. 2012
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. /// T Ono, A Takeshita, U Kishimoto, H Kiyoi, M Okada, T Ymauchi, M Tsuzuki, K Horikawa, M Matuda, K Shinagawa, F Monma, S Ohtake, C Nakaseko, M Takahashi, U Kimura,M Iwanaga, N Asou, adn O Naoe for the Japan Adult Leukemia Study Group. /// Cancer Sci 103(11):1974-1978. 2012
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. /// Y Ito, A Wakita, S Takada, M Mihara, M Gotoh, K Ohyashiki, S Ohtake, S Miyawaki, K Ohnishi, O Naoe. /// Int J Hematol 96(4):485-491.2012
Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. /// S Miyawaki. /// Int J Hematol. Aug;96(2):171-177. 2012
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for eldery patients with acute myeloid leukemia:the JALSG GML200 Study. /// A wakita, H Ohteke, S Takada, F Yagasaki, H Komatsu, Y Miyazaki, et al. /// Int J Hematol 96(4):485-491. 2012
Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. /// T Ono, A Takeshita, U Kishimoto, H Kiyoi, M Okada, T Ymauchi, M Tsuzuki, K Horikawa, M Matuda, K Shinagawa, F Monma, S Ohtake, C Nakaseko, M Takahashi, U Kimura,M Iwanaga, N Asou, adn O Naoe for the Japan Adult Leukemia Study Group. /// Cancer Sci 103(11):1974-1978. 2012
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. /// Y Ito, A Wakita, S Takada, M Mihara, M Gotoh, K Ohyashiki, S Ohtake, S Miyawaki, K Ohnishi, O Naoe. /// Int J Hematol 96(4):485-491.2012
Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group. /// S Miyawaki. /// Int J Hematol. Aug;96(2):171-177. 2012
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. /// Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S,Sunami K,Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, AtsutaY, Kobayashi Y, Naoe T, Emi N. /// Blood. 121:3095-3102.2013
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies. /// Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda T, Miyamura K,Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi J, Takahashi M, Dobashi N, Kiyoi K, Miyazaki Y, Emi N,Kobayashi Y, Ohno R, Naoe T. /// Cancer. 119(18): 3326-3333. 2013
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. /// Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H, Okada M, Inaguma Y, Matsuda M, Yamauchi T, Ohtake S, Izumi T, Nakaseko C, Ishigatsubo Y, Shinagawa K, Takeshita A, Miyazaki Y, Ohnishi K, Miyawaki S, Naoe T; Japan Adult Leukemia Study Group. /// Cancer Sci. 2013 Oct;104(10):1339-1345.
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). /// Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T, Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T. /// Leuk Res. 2013 Sep;37(9):1021-1026.
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies. /// Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda T, Miyamura K,Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi J, Takahashi M, Dobashi N, Kiyoi K, Miyazaki Y, Emi N,Kobayashi Y, Ohno R, Naoe T. /// Cancer. 119(18): 3326-3333. 2013
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. /// Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H, Okada M, Inaguma Y, Matsuda M, Yamauchi T, Ohtake S, Izumi T, Nakaseko C, Ishigatsubo Y, Shinagawa K, Takeshita A, Miyazaki Y, Ohnishi K, Miyawaki S, Naoe T; Japan Adult Leukemia Study Group. /// Cancer Sci. 2013 Oct;104(10):1339-1345.
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). /// Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T, Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T. /// Leuk Res. 2013 Sep;37(9):1021-1026.
Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome. /// Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y, Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T. /// Ann Hematol. 93(6): 957-963. 2014
Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. /// Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T. /// Leukemia. 28(8):1586-1595. 2014
Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. /// Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. /// Bone Marrow Transplant. 2014 Sep 22.
Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. /// F Hayakawa, T Sakura, T Yujiri, E Kondo, K Fujimaki, O Sasaki, J Miyatake, H Handa, Y Ueda, Y Aoyama, S Takada, Y Tanaka, N Usui, S Miyawaki, S Suenobu, K Horibe, H Kiyoi, K Ohnishi, Y Miyazaki. S Ohtake, Y Kobayashi, K Matsuo and T Naoe for the Japan Adult Leukemia Study Group(JALSG). /// Blood Cancer Journal(2014) 4, e252
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. /// Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; The Japan Adult Leukemia Study Group. /// Cancer Science. 105(1):97-104, 2014.
Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. /// Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T. /// Leukemia. 28(8):1586-1595. 2014
Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. /// Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. /// Bone Marrow Transplant. 2014 Sep 22.
Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. /// F Hayakawa, T Sakura, T Yujiri, E Kondo, K Fujimaki, O Sasaki, J Miyatake, H Handa, Y Ueda, Y Aoyama, S Takada, Y Tanaka, N Usui, S Miyawaki, S Suenobu, K Horibe, H Kiyoi, K Ohnishi, Y Miyazaki. S Ohtake, Y Kobayashi, K Matsuo and T Naoe for the Japan Adult Leukemia Study Group(JALSG). /// Blood Cancer Journal(2014) 4, e252
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. /// Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; The Japan Adult Leukemia Study Group. /// Cancer Science. 105(1):97-104, 2014.
Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial. /// Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y, Emi N, Tamaki S, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K, Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T. /// J Clin Oncol. 2015 Jan 10;33(2):228.
Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. /// Yanada M, Kanda J, Ohtake S, Fukuda T, Sakamaki H, Miyamura K, Miyawaki S, Uchida N, Maeda T, gamura-Inoue T, Asou N, Morishima Y, Atsuta Y, Miyazaki Y, Kimura F, Kobayashi Y, Takami A, Naoe T, Kanda Y. /// Eur J Haematol. 2016 Sep;97(3):278-87.
Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. /// Shin Fujisawa, Shuichi Mizuta, Hideki Akiyama, Yasunori Ueda, Yasutaka Aoyama, Yoshihiro Hatta, Kazuhiko Kakihana, Nobuaki Dobashi, Isamu Sugiura, Yasushi Onishi, Tomoya Maeda, Kiyotoshi Imai, Shigeki Ohtake, Yasushi Miyazaki, Kazunori Ohnishi, Keitaro Matsuo, Tomoki Naoe. /// Am J Hematol. 2017;92:367–374.
Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. /// Shun-ichi Kimura, Hiroyuki Fujita, Hideaki Kato, Nobuhiro Hiramoto, Naoko Hosono, Tsutomu Takahashi, Kazuyuki Shigeno, Naoko Hatsumi, Hitoshi Minamiguchi, Junichi Miyatake, Hiroshi Handa, Nobu Akiyama, Yoshinobu Kanda, Minoru Yoshida, Hitoshi Kiyoi, Yasushi Miyazaki, Tomoki Naoe, Japan Adult Leukemia Study Group (JALSG). /// Supportive Care in Cancer, 25(11), 3515-3521.DOI 10.1007/s00520-017-3775-8.
Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. /// Shun-ichi Kimura, Hiroyuki Fujita, Hideaki Kato, Nobuhiro Hiramoto, Naoko Hosono, Tsutomu Takahashi, Kazuyuki Shigeno, Naoko Hatsumi, Hitoshi Minamiguchi, Junichi Miyatake, Hiroshi Handa, Nobu Akiyama, Yoshinobu Kanda, Minoru Yoshida, Hitoshi Kiyoi, Yasushi Miyazaki, Tomoki Naoe, Japan Adult Leukemia Study Group (JALSG). /// Supportive Care in Cancer, 25(11), 3515-3521.DOI 10.1007/s00520-017-3775-8.
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. /// Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, Koichi Miyamura, Yoshio Saburi, Yoshihiro Hatta, Yasuhiko Miyata, Shinichi Kobayashi, Kensuke Usuki, Itaru Matsumura, Yosuke Minami, Noriko Usui, Tetsuya Fukuda, Satoru Takada, Maho Ishikawa, Katsumichi Fujimaki, Hiroshi Gomyo, Osamu Sasaki, Kohshi Ohishi, Takaaki Miyake, Kiyotoshi Imai, Hitoshi Suzushima, Hideki Mitsui, Kazuto Togitani, Toru Kiguchi, Yoshiko Atsuta, Shigeki Ohtake, Kazunori Ohnishi, Yukio Kobayashi, Hitoshi Kiyoi, Yasushi Miyazaki, Tomoki Naoe, The Japan Adult Leukemia Study Group. /// Int J Hematol. doi: 10.1007/s12185-017-2334-x.
High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG. /// T Sakura, F Hayakawa, I Sugiura, T Murayama, K Imai, N Usui, S Fujisawa, T Yamauchi, T Yujiri, K Kakihana, Y Ito, H Kanamori, Y Ueda, Y Miyata, M Kurokawa, N Asou, K Ohnishi, S Ohtake, Y Kobayashi, K Matsuo, H Kiyoi, Y Miyazaki, T Naoe, for the Japan Adult Leukemia Study Group (JALSG). /// Leukemia. doi: 10.1038/leu.2017.283.
Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. /// Kaito Harada, Noriko Doki, Takeshi Hagino, Shuichi Miyawaki, Shigeki Ohtake, Hitoshi Kiyoi, Yasushi Miyazaki, Hiroyuki Fujita, Noriko Usui, Hirokazu Okumura, Koichi Miyamura, Chiaki Nakaseko, Atsushi Fujieda, Tadashi Nagai, Takahisa Yamane, Hisashi Sakamaki, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno, Kazuteru Ohashi. /// Ann Hematol. doi:10.1007/s00277-017-3156-x.
Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. /// Yachiyo Kuwatsuka, Daisuke Tomizawa, Rika Kihara, Yasunobu Nagata, Norio Shiba, Yuka Iijima‑Yamashita, Akira Shimada, Takao Deguchi, Hayato Miyachi, Akio Tawa, Takashi Taga, Akitoshi Kinoshita, Hideki Nakayama, Nobutaka Kiyokawa, Akiko Moriya Saito, Katsuyoshi Koh, Hiroaki Goto, Yoshiyuki Kosaka, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Yasushi Miyazaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Shinichi Kobayashi, Kunio Kitamura, Emiko Sakaida, Seishi Ogawa, Tomoki Naoe, Yasuhide Hayashi, Keizo Horibe, Atsushi Manabe, Shuki Mizutani, Souichi Adachi, Hitoshi Kiyoi. /// Int J Hematol. DOI 10.1007/s12185-017-2340-z.
Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. /// Rena Kamijo, Hidehiro Itonaga, Rika Kihara, Yasunobu Nagata, Tomoko Hata, Norio Asou, Shigeki Ohtake, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Seishi Ogawa, Tomoki Naoe, Hitoshi Kiyoi, Yasushi Miyazaki. /// Leukemia Research 65 (2018) 34–41.
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. /// Yasuhiko Harada, Yasunobu Nagata, Rika Kihara, Yuichi Ishikawa, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Shinichi Kobayashi, Kunio Kitamura, Emiko Sakaida, Makoto Onizuka, Akihiro Takeshita, Fumihiro Ishida, Hitoshi Suzushima, Kenichi Ishizawa, Tomoki Naoe, Itaru Matsumura, Yasushi Miyazaki, Seishi Ogawa, Hitoshi Kiyoi, for the Japan Adult Leukemia Study Group JALSG. /// Leukemia Research 66 (2018) 20–27.
Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200. /// Kaito Harada, Noriko Doki, Yasushi Miyazaki, Atsushi Wakita, Shigeki Ohtake, Satoru Takada, Hirokazu Komatsu, Kohmei Kubo, Akihiro Takeshita, Yoko Adachi, Hitoshi Kiyoi, Takuhiro Yamaguchi, Minoru Yoshida, Tomoki Naoe, Kazuteru Ohashi. /// Annals of Hematology. doi: 10.1007/s00277-018-3281-1.
Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001–2005 using the Japan Adult Leukemia Study Group AML201 protocols. /// Hideaki Kato, Hiroyuki Fujita, Nobu Akiyama, Shun-ichi Kimura, Nobuhiro Hiramoto, Naoko Hosono, Tsutomu Takahashi, Kazuyuki Shigeno, Hitoshi Minamiguchi, Junichi Miyatake, Hiroshi Handa, Yoshinobu Kanda, Minoru Yoshida, Shuichi Miyawaki, Shigeki Ohtake, Tomoki Naoe, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, Japan Adult Leukemia Study Group. /// Supportive Care in Cancer. doi: 10.1007/s00520-018-4292-0.
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. /// Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T. /// Ann Hematol. 2018 Sep;97(9):1535-1545.
Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. /// Naomi Kawashima, Akimi Akashi, Yasunobu Nagata, Rika Kihara, Yuichi Ishikawa, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Kunio Kitamura, Emiko Sakaida, Akihiro Takeshita, Hitoshi Suzushima, Tomoki Naoe, Itaru Matsumura, Yasushi Miyazaki, Seishi Ogawa, Hitoshi Kiyoi, for the Japan Adult Leukemia Study Group (JALSG). /// Annals of Hematology. doi： 10.1007/s00277-018-3492-5.
Exome analysis of treatment-related AML after APL suggestssecondary evolution /// Tianjiao Wang, Meagan A. Jacoby, Eric J. Duncavage, Christopher A. Miller, Sharon Heath, Ramy Rahme, Pierre Fenaux, Lionel Ades, Aline Renneville, Bruno Cassinat, Akihiro Takeshita, Norio Asou, Yasushi Miyazaki, Hitoshi Kiyoi, Farhad Ravandi, Peter Westervelt, Lukas D. Wartman, John S. Welch /// "British Journal of Haematology doi: 10.1111/bjh.15681"
High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG. /// T Sakura, F Hayakawa, I Sugiura, T Murayama, K Imai, N Usui, S Fujisawa, T Yamauchi, T Yujiri, K Kakihana, Y Ito, H Kanamori, Y Ueda, Y Miyata, M Kurokawa, N Asou, K Ohnishi, S Ohtake, Y Kobayashi, K Matsuo, H Kiyoi, Y Miyazaki, T Naoe, for the Japan Adult Leukemia Study Group (JALSG). /// Leukemia. doi: 10.1038/leu.2017.283.
Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. /// Kaito Harada, Noriko Doki, Takeshi Hagino, Shuichi Miyawaki, Shigeki Ohtake, Hitoshi Kiyoi, Yasushi Miyazaki, Hiroyuki Fujita, Noriko Usui, Hirokazu Okumura, Koichi Miyamura, Chiaki Nakaseko, Atsushi Fujieda, Tadashi Nagai, Takahisa Yamane, Hisashi Sakamaki, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno, Kazuteru Ohashi. /// Ann Hematol. doi:10.1007/s00277-017-3156-x.
Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. /// Yachiyo Kuwatsuka, Daisuke Tomizawa, Rika Kihara, Yasunobu Nagata, Norio Shiba, Yuka Iijima‑Yamashita, Akira Shimada, Takao Deguchi, Hayato Miyachi, Akio Tawa, Takashi Taga, Akitoshi Kinoshita, Hideki Nakayama, Nobutaka Kiyokawa, Akiko Moriya Saito, Katsuyoshi Koh, Hiroaki Goto, Yoshiyuki Kosaka, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Yasushi Miyazaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Shinichi Kobayashi, Kunio Kitamura, Emiko Sakaida, Seishi Ogawa, Tomoki Naoe, Yasuhide Hayashi, Keizo Horibe, Atsushi Manabe, Shuki Mizutani, Souichi Adachi, Hitoshi Kiyoi. /// Int J Hematol. DOI 10.1007/s12185-017-2340-z.
Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. /// Rena Kamijo, Hidehiro Itonaga, Rika Kihara, Yasunobu Nagata, Tomoko Hata, Norio Asou, Shigeki Ohtake, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Seishi Ogawa, Tomoki Naoe, Hitoshi Kiyoi, Yasushi Miyazaki. /// Leukemia Research 65 (2018) 34–41.
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. /// Yasuhiko Harada, Yasunobu Nagata, Rika Kihara, Yuichi Ishikawa, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Shinichi Kobayashi, Kunio Kitamura, Emiko Sakaida, Makoto Onizuka, Akihiro Takeshita, Fumihiro Ishida, Hitoshi Suzushima, Kenichi Ishizawa, Tomoki Naoe, Itaru Matsumura, Yasushi Miyazaki, Seishi Ogawa, Hitoshi Kiyoi, for the Japan Adult Leukemia Study Group JALSG. /// Leukemia Research 66 (2018) 20–27.
Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200. /// Kaito Harada, Noriko Doki, Yasushi Miyazaki, Atsushi Wakita, Shigeki Ohtake, Satoru Takada, Hirokazu Komatsu, Kohmei Kubo, Akihiro Takeshita, Yoko Adachi, Hitoshi Kiyoi, Takuhiro Yamaguchi, Minoru Yoshida, Tomoki Naoe, Kazuteru Ohashi. /// Annals of Hematology. doi: 10.1007/s00277-018-3281-1.
Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001–2005 using the Japan Adult Leukemia Study Group AML201 protocols. /// Hideaki Kato, Hiroyuki Fujita, Nobu Akiyama, Shun-ichi Kimura, Nobuhiro Hiramoto, Naoko Hosono, Tsutomu Takahashi, Kazuyuki Shigeno, Hitoshi Minamiguchi, Junichi Miyatake, Hiroshi Handa, Yoshinobu Kanda, Minoru Yoshida, Shuichi Miyawaki, Shigeki Ohtake, Tomoki Naoe, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, Japan Adult Leukemia Study Group. /// Supportive Care in Cancer. doi: 10.1007/s00520-018-4292-0.
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. /// Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T. /// Ann Hematol. 2018 Sep;97(9):1535-1545.
Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. /// Naomi Kawashima, Akimi Akashi, Yasunobu Nagata, Rika Kihara, Yuichi Ishikawa, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Kunio Kitamura, Emiko Sakaida, Akihiro Takeshita, Hitoshi Suzushima, Tomoki Naoe, Itaru Matsumura, Yasushi Miyazaki, Seishi Ogawa, Hitoshi Kiyoi, for the Japan Adult Leukemia Study Group (JALSG). /// Annals of Hematology. doi： 10.1007/s00277-018-3492-5.
Exome analysis of treatment-related AML after APL suggestssecondary evolution /// Tianjiao Wang, Meagan A. Jacoby, Eric J. Duncavage, Christopher A. Miller, Sharon Heath, Ramy Rahme, Pierre Fenaux, Lionel Ades, Aline Renneville, Bruno Cassinat, Akihiro Takeshita, Norio Asou, Yasushi Miyazaki, Hitoshi Kiyoi, Farhad Ravandi, Peter Westervelt, Lukas D. Wartman, John S. Welch /// "British Journal of Haematology doi: 10.1111/bjh.15681"
Randomized study of imatinib for chronic myeloid leukemia: comparing
standard dose escalation with aggressive escalation /// Koichi Miyamura,Kazunori Ohnishi,Shigeki Ohtake,Noriko Usui,Chiaki Nakaseko,Hiroyuki Fujita,Shin Fujisawa,Toru Sakura,Hirokazu Okumura,Noriyoshi Iriyama,Nobuhiko Emi,Katsumichi Fujimaki,Sumihisa Honda,Yasushi Miyazaki,and
Tomoki Naoe /// Blood Advances 2019 3:312-319; DOI:10.1182/bloodadvances.2018025981
Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. /// Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki, Masaru Nakagawa, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Hiroaki Furumaki, Yukako Obata, Hiroyuki Fujita, Masamitsu Yanada, Yoshinobu Maeda, Noriko Usui, Yukio Kobayashi, Hitoshi Kiyoi, Shigeki Ohtake, Itaru Matsumura, Tomoki Naoe, Yasushi Miyazaki, and the Japanese Adult Leukemia Study Group. /// Leukemia 2019;33(2):358-370. doi: 10.1038/s41375-018-0233-7.
Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. /// Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki, Masaru Nakagawa, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Hiroaki Furumaki, Yukako Obata, Hiroyuki Fujita, Masamitsu Yanada, Yoshinobu Maeda, Noriko Usui, Yukio Kobayashi, Hitoshi Kiyoi, Shigeki Ohtake, Itaru Matsumura, Tomoki Naoe, Yasushi Miyazaki, and the Japanese Adult Leukemia Study Group. /// Leukemia 2019;33(2):358-370. doi: 10.1038/s41375-018-0233-7.
Prospective evaluation of prognostic impact of KIT mutations on acute
myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11" /// Yuichi Ishikawa,Naomi Kawashima,Yoshiko Atsuta,Isamu Sugiura,Masashi Sawa,Nobuaki Dobashi,Hisayuki Yokoyama,Noriko Doki,Akihiro Tomita,Toru Kiguchi,Shiro Koh,Heiwa Kanamori,Noriyoshi Iriyama,Akio Kohno,Yukiyoshi Moriuchi,Noboru Asada,Daiki Hirano,Kazuto Togitani,Toru Sakura,Maki Hagihara,Tatsuki Tomikawa,Yasuhisa Yokoyama,Norio Asou,Shigeki Ohtake,Itaru Matsumura,Yasushi Miyazaki,Tomoki Naoe,and Hitoshi Kiyoi,for the Japan Adult Leukemia Study Group /// Blood Advances (2020) 4 (1): 66-75; DOI:10.1182/bloodadvances.2019000709
Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study /// Naomi Kawashima, Yuichi Ishikawa, Yoshiko Atsuta, Masashi Sawa, Yukiyasu Ozawa, Masaki Hayashi, Akio Kohno, Akihiro Tomita, Tomoya Maeda, Emiko Sakaida, Kensuke Usuki, Maki Hagihara, Heiwa Kanamori, Hiroshi Matsuoka, Miki Kobayashi, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi for the Japan Adult Leukemia Study Group (JALSG) /// Cancer Science. 2020;00:1–10; DOI: 10.1111/cas.14448
Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature /// Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Hiroaki Furumaki, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki, Masaru Nakagawa, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Hitoshi Minamiguchi, Hiroyuki Fujita, Masamitsu Yanada, Yoshinobu Maeda, Noriko Usui, Yukio Kobayashi, Hitoshi Kiyoi, Shigeki Ohtake, Itaru Matsumura, Tomoki Naoe, Yasushi Miyazaki and the Japan Adult Leukemia Study Group /// Cancers 2020, 12, 1444; doi:10.3390/cancers12061444
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia /// Hitoshi Minamiguchi, Hiroyuki Fujita, Yoshiko Atsuta, Norio Asou, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki, Yoshihito Uchino, Akihiro Tomita, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Masamitsu Yanada, Yoshinobu Maeda, Masako Iwanaga, Noriko Usui, Yukio Kobayashi, Shigeki Ohtake, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Akihiro Takeshita, on behalf of the Japan Adult Leukemia Study Group /// Annals of Hematology. DOI: 10.1007/s00277-020-04245-6
Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study /// Naomi Kawashima, Yuichi Ishikawa, Yoshiko Atsuta, Masashi Sawa, Yukiyasu Ozawa, Masaki Hayashi, Akio Kohno, Akihiro Tomita, Tomoya Maeda, Emiko Sakaida, Kensuke Usuki, Maki Hagihara, Heiwa Kanamori, Hiroshi Matsuoka, Miki Kobayashi, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi for the Japan Adult Leukemia Study Group (JALSG) /// Cancer Science. 2020;00:1–10; DOI: 10.1111/cas.14448
Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature /// Akihiro Takeshita, Norio Asou, Yoshiko Atsuta, Hiroaki Furumaki, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki, Masaru Nakagawa, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Hitoshi Minamiguchi, Hiroyuki Fujita, Masamitsu Yanada, Yoshinobu Maeda, Noriko Usui, Yukio Kobayashi, Hitoshi Kiyoi, Shigeki Ohtake, Itaru Matsumura, Tomoki Naoe, Yasushi Miyazaki and the Japan Adult Leukemia Study Group /// Cancers 2020, 12, 1444; doi:10.3390/cancers12061444
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia /// Hitoshi Minamiguchi, Hiroyuki Fujita, Yoshiko Atsuta, Norio Asou, Toru Sakura, Yasunori Ueda, Masashi Sawa, Nobuaki Dobashi, Yasuhiro Taniguchi, Rikio Suzuki, Yoshihito Uchino, Akihiro Tomita, Shigehisa Tamaki, Maki Hagihara, Katsumichi Fujimaki, Masamitsu Yanada, Yoshinobu Maeda, Masako Iwanaga, Noriko Usui, Yukio Kobayashi, Shigeki Ohtake, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Akihiro Takeshita, on behalf of the Japan Adult Leukemia Study Group /// Annals of Hematology. DOI: 10.1007/s00277-020-04245-6
